



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G01N 33/566, 33/569	A1	(11) International Publication Number: WO 99/31510 (43) International Publication Date: 24 June 1999 (24.06.99)
(21) International Application Number: PCT/US98/24014 (22) International Filing Date: 12 November 1998 (12.11.98) (30) Priority Data: 08/990,125 12 December 1997 (12.12.97) US (71) Applicant (for all designated States except US): AL- PHA-BETA TECHNOLOGY, INC. [US/US]; One Innovation Drive, Worcester, MA 01605 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): WAKSHULL, Eric, M. [US/US]; 13 Whittaker Lane, Princeton, MA 01541 (US). MACKIN, William, M. [US/US]; 5 Colicum Drive, Charlton, MA 01507 (US). ZIMMERMAN, Janet, W. [US/US]; 165 Codman Hill Road, Harvard, MA 01451 (US). FISETTE, Leslie, W. [US/US]; 80 New Westminster Road, Hubbardston, MA 01452 (US). (74) Agents: CARROLL, Alice, O. et al.; Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA 02421 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: β (1-3)-GLUCAN DIAGNOSTIC ASSAYS		
(57) Abstract Methods of isolating β (1-3)-glucan or β (1-3)-glucan-containing organisms in a sample, or of detecting the presence of β (1-3)-glucan or β (1-3)-glucan-containing organisms in a sample, utilizing binding agents for β (1-3)-glucan, such as LacCer, GalCer, globotriaosylceramide and asialoganglioside-GM1, are described. Methods of diagnosing fungal infection, by detecting β (1-3)-glucan or β (1-3)-glucan-containing organisms, are also described. Antibodies and kits useful in the methods are also disclosed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

β (1-3)-GLUCAN DIAGNOSTIC ASSAYS

RELATED APPLICATIONS

This application is a Continuation-in-part application of International Application PCT/US97/07445, filed on May 1, 1997, which is a Continuation-in-part application of U.S. serial number 08/797,696, filed January 31, 1997. The teachings of the prior applications are incorporated herein in their entirety.

BACKGROUND OF THE INVENTION

10 Immunocompromised patients are susceptible to a variety of neoplastic, protozoal, viral, bacterial and fungal diseases; of these, bacterial, viral and fungal infections result in the greatest mortality (Bartlett, M. and J. Smith, *Clin. Microbiol. Rev.* 4:137 (1991);
15 Bodey, G. et al., *Dur. J. Clin. Microbiol. Infect. Dis.* 11:99 (1992); Sternberg, S., *Science* 266:1632 (1994); Cox, G. and J. Perfect, *Curr. Opin. Infect. Dis.* 6:422 (1993); Deepe, G. and W. Bullock, *Dur. J. Clin. Microbiol. Infect. Dis.* 9:377 (1990); Fox, J. L., *ASM News* 59:515 (1993); Kujath, P., *Mycoses* 35:225 (1992);
20 Pfaller, M. and R. Wenzel, *Dur. J. Clin. Microbiol. Infect. Dis.* 11:287 (1992); and Samonis, G. and D. Bafaloukos, *In vivo* 6:183 (1992)). Systemic fungal infections are now an important medical problem in the
25 care of immunocompromised patients. Fungal infections in immunocompromised patients are mainly the result of opportunistic infections by normally harmless, asymptomatic commensals, which can be pathogenic under certain

-2-

conditions (Odd, J., *Antimicrob. Chemother.* 31:463 (1993); Rhodes, J. et al., *J. Med. Vet. Myc.* 20:113 (1992); Saral, R. *Rev. Infect. Dis.* 13:487 (1991)). Species of *Cryptococcus*, *Candida*, *Coccidioides*, *Histoplasma*,
5 *Blastomyces*, *Sporothrix* and *Aspergillus*, as well as other opportunistic fungi, are important causative agents; of these, *Candida* species, especially *C. albicans*, are the most common. Candidemia accounts for 8-10% of all hospital-acquired bloodstream infections and *Candida*
10 species are the fourth most common cause of nosocomial septicemias. Mortality rates associated with systemic *Candida* infections are estimated to be as high as 50% of infected patients. Infections caused by other types of fungi (e.g., *Aspergillus*, *Cryptococcus*) are also common in
15 immunocompromised patients and carry significant treatment costs and mortality levels (Meunier, F., *Amer. J. Med.* 99 (Suppl. 6A):60S-67S (1995)).

A variety of approaches have been used to diagnose fungal infections in humans; each method has distinct
20 limitations. Blood cultures often fail to detect existing infections and may take two to five days to detect fungal growth, a period of time which an infected patient often cannot survive. Assays for fungal-specific metabolites are also used. For example,
25 an assay for D-arabinitol can be performed by monitoring of oxidation of D-arabinitol by D-arabinitol dehydrogenase (Soyama, K. and E. Ono, *Clin. Chim. Acta* 149:149 (1985); Soyama, K. and E. Ono, *Clin. Chim. Acta.* 168:259 (1987)). However, D-arabinitol dehydrogenase also reacts with D-
30 mannitol naturally existing in serum samples, resulting in an artificially high oxidation rate. Furthermore, both D-

-3-

mannitol and D-arabinitol are elevated during renal failure (Reiss, E. and C. Morrison, *J. Clin. Microbiol. Rev.* 6:311-322 (1993)).

Immunoassays to detect antibody binding to a fungal
5 marker antigen have also been developed: for example, an
assay for enolase secreted by *C. albicans* is described
(Matthews, R.C. et al., *Lancet* i:1415 (1984), Matthews,
R.C. et al., *J. Clin. Microbiol.* 26:459 (1988), and Walsh,
et al., *New. Engl. J. Med.* 324:1026 (1991)). However, the
10 capture antibody is believed to react with enolases from
sources other than *C. albicans* (Reiss, E. and C. Morrison,
J. Clin. Microbiol. Rev. 6:311-322 (1993), and the
sensitivity is limited (Mitsutake, K. et al., *J. Clin.*
Microbiol. 34:1918-1921 (1996)). Another assay uses
15 detection of aspartyl proteinase secreted from *C. albicans*.
(Staib, R., *Sabouraudia* 4:187 (1965); Reiss, E. and C.J.
Morrison, *Clin. Microbiol. Rev.* 6:311 (1993)). An assay to
detect secreted $\beta(1-3)$ -glucan, based on activation of
factor G of the *Limulus* coagulation enzyme cascade, is also
20 described (U.S. 5,266,461); however, this assay is
sensitive to a number of interfering compounds, including
compounds of fungal origin (Matsumoto, T.M. et al., *Urol.*
Res. 21:21-117-120 (1993)).

Additional assays include immunological assays to
25 detect antigens, such as cell-wall mannan, circulating
through the host during fungal infection, by
radioimmunoassay (RIA) (Weiner, M.H. and M. Coats-Stephen,
J. Infect. Dis. 140:989 (1979)), inhibition enzyme
immunoassay (Meckstroth, K.L. et al., *J. Infect. Dis.*
30 144:24 (1981); Segal, E. et al., *J. Clin. Microbiol.*
10:116-118 (1979)), and double antibody sandwich enzyme

-4-

immunoassay (Lew, M.A. et al., *J. Infect. Dis.* 145:45-56 (1982)). Reliability of these tests may be hampered by the presence of anti-mannan antibodies and cell-wall binding proteins. Furthermore, the concentration of the antigen is low, even with severe infection, so detection can be difficult.

Amplification of sample DNA by polymerase chain reaction (PCR) has been used with fungal-specific nucleotide probes to detect the presence of fungal DNA (U.S. 5,489,513; 5,426,027; and 5,324,632). These methods are complicated, expensive, time-consuming and often are sensitive to interfering materials found in the host sample (Reiss, E. and C. Morrison, *J. Clin. Microbiol. Rev.* 6:311-323 (1993)).

Thus, each of the variety of methods for diagnosing fungal infection has deficiencies, including unreliability, interfering agents, or a need for sophisticated equipment or trained personnel. Because of the increasing incidence of fungal infections, a need remains for accurate, simple, quantitative and expedient methods for diagnosis of fungal infections.

SUMMARY OF THE INVENTION

The present invention is drawn to methods of isolating, concentrating or purifying $\beta(1-3)$ -glucans, as well as $\beta(1-3)$ -glucan-containing organisms, and also to assays to quantify the amount of $\beta(1-3)$ -glucans, or $\beta(1-3)$ -glucan-containing organisms in a test sample. The test sample can be a liquid or a solid, and can originate from various sources, including complex animal sources (e.g., a biological fluid, such as blood, serum, plasma, urine,

-5-

feces, mucus, sputum, bile, ascites fluid, wound secretions, vaginal excretions, synovial fluid, cerebrospinal fluid, peritoneal lavage fluid, lung lavage fluid, ocular fluid, saliva or whole tissue extract;

5 alternatively, the test sample can be solid specimen, such as skin or other tissue); plant sources (plant tissue, plant tissue extract, fruit or fruit extracts, seeds or seed extracts, sap, or homogenates); bacterial cells; viral cells; fungal cells; tissue cultures; environmental
10 sources; food sources; or fermentation process sources.

In the methods of the invention, a $\beta(1-3)$ -glucan binding agent is used to capture or purify $\beta(1-3)$ -glucans and/or $\beta(1-3)$ -glucan-containing organisms from a test sample. $\beta(1-3)$ -glucan binding agents are compounds that
15 have an affinity for underivatized, aqueous soluble $\beta(1-3)$ -glucan, including lactosyl ceramide (LacCer) (human), LacCer (bovine), LacCer (porcine), galactosyl ceramide (GalCer) I, GalCer II, globotriaosyl ceramide (globotriaosylCer), and asialoganglioside-GM1. The $\beta(1-3)$ -
20 glucan binding agent(s), or the test sample, can be coupled or attached to a solid phase or a fluid phase. The test sample is contacted with a $\beta(1-3)$ -glucan binding agent, under conditions that are suitable for binding of any $\beta(1-3)$ -glucan that may be present in the test sample to the
25 $\beta(1-3)$ -glucan binding agent; resultant complexes of $\beta(1-3)$ -glucan and $\beta(1-3)$ -glucan binding agent ("primary complexes") can then be isolated, in order to isolate $\beta(1-3)$ -glucan. In another embodiment, the primary complexes can be detected, in order to detect $\beta(1-3)$ -glucan or $\beta(1-3)$ -glucan-containing organisms in the test sample: the
30 presence of primary complexes is indicative of the presence

-6-

of $\beta(1-3)$ -glucan or $\beta(1-3)$ -glucan-containing organisms. In another embodiment, the presence of $\beta(1-3)$ -glucan can be detected through a competition assay, in which labeled underivatized, aqueous soluble $\beta(1-3)$ -glucan and $\beta(1-3)$ -glucan binding agents are incubated with the test sample; the amount of $\beta(1-3)$ -glucan in the test sample is inversely proportional to the amount of complexes of labeled underivatized, aqueous soluble $\beta(1-3)$ -glucan and $\beta(1-3)$ -glucan binding agents. The presence of $\beta(1-3)$ -glucan (or of $\beta(1-3)$ -glucan-containing organisms) in the test sample is indicative of a fungal infection or fungal contamination. Antibodies that can be used in these methods and assays, as well as kits that can be used in these methods and assays, are also within the scope of the invention.

The methods and assays of the invention allow for specific, highly sensitive detection of $\beta(1-3)$ -glucans in a test sample, facilitating diagnosis of fungemias and detection of fungal contamination, without requiring expensive equipment or trained personnel.

DETAILED DESCRIPTION OF THE FIGURES

Figure 1 is a graphic illustration of a comparison of underivatized, aqueous soluble $\beta(1-3)$ -glucan and single helix $\beta(1-3)$ -glucan (single helix) competition of ^3H -underivatized, aqueous soluble $\beta(1-3)$ -glucan binding in three assay formats. Underivatized, aqueous soluble $\beta(1-3)$ -glucan or single helix glucan was used at designated concentrations to compete for ^3H -underivatized, aqueous soluble $\beta(1-3)$ -glucan binding to lactosyl ceramide (LacCer) in a 96-well plate (triangles), or to lactosyl ceramide in

-7-

reconstituted membranes (squares), or to human leukocyte membranes (HLM) (circles). Open symbols represent underivatized, aqueous soluble $\beta(1-3)$ -glucan, and closed symbols represent single helix. Maximum competition was assigned at the highest concentration of underivatized, aqueous soluble $\beta(1-3)$ -glucan used as competitor in each type of assay.

Figure 2 is a graphic illustration of data showing that underivatized, aqueous soluble $\beta(1-3)$ -glucan and high molecular weight underivatized, aqueous soluble $\beta(1-3)$ -glucan (very high molecular weight glucan (VHMW glucan) compete more effectively for ^3H -underivatized, aqueous soluble $\beta(1-3)$ -glucan binding to lactosyl ceramide (LacCer) in a 96-well plate assay than do single helix or laminarin. Underivatized, aqueous soluble $\beta(1-3)$ -glucan (circles), single helix (closed squares), laminarin (crosses) and high molecular weight underivatized, aqueous soluble $\beta(1-3)$ -glucan (VHMW glucan) (hatched squares) were used at designated concentrations to compete for ^3H -underivatized, aqueous soluble $\beta(1-3)$ -glucan binding to lactosyl ceramide (bovine) in a 96-well plate assay. "% control binding" means the percent of binding with no competitor present in the reaction mixture.

Figure 3 is a graphic illustration of data showing that GalCer binds underivatized, aqueous soluble $\beta(1-3)$ -glucan.

Figure 4 is a graphic illustration of data showing that GalCer and LacCer bind significantly more underivatized, aqueous soluble $\beta(1-3)$ -glucan in a 96-well plate assay, using *Limulus* amebocyte lysate as a detection agent, than does GlcCer. Negative control (grey boxes),

-8-

GalCer (hatched boxes), GlcCer (open boxes), LacCer (solid boxes).

Figure 5 is a graphic illustration of data showing that GalCer bound three times as much tritiated $\beta(1-3)$ -glucan as LacCer in a capture experiment.

Figure 6 is a graphic illustration of data showing the ability of GalCer to capture different conformational states of soluble $\beta(1-3)$ -glucan. PGG-Glucan (open boxes), random coil glucan, (dotted boxes), single chain glucan (solid boxes), triple helix glucan (striped boxes), very high molecular weight glucan (shaded boxes).

Figure 7 is a graphic illustration of data showing the ability of GalCer to capture aqueous soluble glucan from *Candida albicans* in normal human urine (open triangles), human plasma (open circles), human plasma treated with PCA (closed circles) and buffer (closed squares).

Figure 8 is a graphic illustration of data showing that antibody BfD IV was most sensitive, when compared with antibodies BfD I, BfD II, BfD III, and a commercial antibody, in detecting soluble $\beta(1-3)$ -glucan bound to GalCer.

DETAILED DESCRIPTION OF THE INVENTION

The invention is based on a discovery that several glycosphingolipids exhibit significant specific binding to a component of fungal cell walls, $\beta(1-3)$ -glucan, and particularly, to ^3H -underivatized, aqueous soluble $\beta(1-3)$ -glucan (PGG-Glucan). Underivatized, aqueous soluble $\beta(1-3)$ -glucans are also described in U.S. Serial Nos. 08/400,488, 08/432,303, 08/373,251 and 08/469,233 and U.S.

-9-

Patent Nos. 5,322,841, 5,488,040, 5,532,223, 5,622,939 and 5,633,369.

The glycosphingolipids include lactosyl ceramides (LacCer), galactosyl ceramides (GalCer), globotriaosyl
5 ceramides, and asialoganglioside-GM1, from various sources. Table 1 sets forth the specific binding of various glycosphingolipids, as assessed by a binding assay in 96-well plates (see Examples for description of Experiments).

10 Table 1: Specific binding of ^3H -underivatized, aqueous soluble $\beta(1-3)$ -glucan (PGG-Glucan) to various sphingolipids in a 96-well plate binding assay

		^3H -PGG-Glucan bound
		<u>(ng/μg sphingolipid)</u>
	Sphingolipid	
	LacCer (HLM)	3.14 \pm 0.29
15	LacCer (bovine)	2.18 \pm 0.39
	LacCer (porcine)	2.35 \pm 0.23
	GalCer I	1.02 \pm 0.32
	GalCer II	3.90 \pm 0.14
	Ceramides	0.02 \pm 0.01
20	Sulfatides	0.00 \pm 0.01
	Sphingosine	0.02 \pm 0.00
	Psychosine	0.09 \pm 0.00
	Asialoganglioside-GM2	0.00 \pm 0.01
	Globoside	0.00 \pm 0.01
25	GlobotriaosylCer	0.84 \pm 0.13
	Glucocerebrosides (GlcCer)	0.12 \pm 0.03
	Asialoganglioside-GM1	0.50 \pm 0.10

These compounds have in common a terminal galactose, which may therefore be involved in binding interactions between
30 ^3H -underivatized, aqueous soluble $\beta(1-3)$ -glucan and the glycosphingolipid. A terminal galactose alone is not

-10-

sufficient for binding, however, since psychosine (1-galactosyl sphingosine) does not show appreciable binding. This compound lacks the fatty acid portion of ceramide.

5 While several fatty acid structures in LacCer can support binding of ^3H -underivatized, aqueous soluble glucan, as shown with HPLC fractionated LacCer from HLM in Table 2, the carbon-carbon double bond found in C18:1 sphingosine is apparently important for binding, since the
10 commercially available dihydro-sphingosine LacCers do not bind.

Table 2: Specific binding of ^3H -underivatized, aqueous soluble $\beta(1-3)$ -glucan (PGG-Glucan) to LacCer of defined structures in the 96-well plate binding
15 assay

		^3H -PGG-Glucan bound	
	Fatty Acid	Long Chain Base	(ng/ μg LacCer)
20	LacCer (HLM) C16:0	C18:1	3.31
	C18:0	C18:1	1.93
	C24:2	C18:1	2.01
	C24:1	C18:1	2.31
	C22:0	C18:1	3.57
	C24:0	C18:1	3.14
25	N-Palmitoyl-DL-dihydrolactocerebroside C16:0	C18:0	0.00
	N-Stearoyl-DL-dihydrolactocerebroside C18:0	C18:0	0.00
30	N-Lignoceroyl-DL-dihydrolactocerebroside C24:0	C18:0	0.00

The binding of ^3H -underivatized, aqueous soluble $\beta(1-3)$ -glucan to LacCer was also found to be temperature

-11-

dependent, similar to that with HLM. Binding occurs at 37°C, but not at 4°C, as indicated in Table 3. The temperature specificity was seen with two different sources of LacCer.

- 5 Table 3: Temperature dependence of ³H-underivatized, aqueous soluble β (1-3)-glucan (PGG-Glucan) specific binding to lactosyl ceramides

	<u>Temperature</u>	<u>³H-PGG-Glucan bound (ng/μg LacCer)</u>
10 LacCer (HLM)	37°C	1.76
	4°C	0.00
LacCer (bovine)	37°C	2.50
	4°C	0.01

The conformer specificity of competition for ³H-underivatized, aqueous soluble β (1-3)-glucan binding was also similar to that previously described with HLM. As shown in Figure 1, underivatized, aqueous soluble β (1-3)-glucan competes for ³H-underivatized, aqueous soluble β (1-3)-glucan binding to HLM, and to LacCer in both the 96-well assay and the reconstitution assay to the same degree. In contrast, single helix (SH) glucan does not compete efficiently in any of the assays. Also, Network, a glucan preparation comprising glucan that is primarily in the triple helix conformation and has a molecular weight of greater than one million, competes similarly to underivatized, aqueous soluble β (1-3)-glucan, while laminarin does not compete efficiently for ³H-underivatized, aqueous soluble β (1-3)-glucan binding to LacCer in the 96-well plate assay (see Figure 2).

30 From these results, an *in vivo* binding agent for underivatized, aqueous soluble β (1-3)-glucan is LacCer.

-12-

Other compounds tested as described above also have an affinity for underivatized, aqueous soluble $\beta(1-3)$ -glucan; these compounds are also intended to be encompassed by the term " $\beta(1-3)$ -glucan binding agent" as used herein. From this work, it appears that there are three characteristics which determine the affinity of a compound for underivatized, aqueous soluble $\beta(1-3)$ -glucan: length of the fatty acid chain of the compound, presence of a terminal galactose in the compound, and presence or absence of a double bond in the sphingosine portion of the compound. Specifically, compounds shown herein to have an affinity for underivatized, aqueous soluble $\beta(1-3)$ -glucan, have a fatty acid chain of from about 16 to about 24 carbons in length, contain a terminal galactose, and contain a double bond in the sphingosine portion. However, compounds having fatty acid chains of less than 16 and greater than 24 carbons are also contemplated by the term, " $\beta(1-3)$ -glucan binding agent", provided that they have an affinity for underivatized, aqueous soluble $\beta(1-3)$ -glucan. Furthermore, as used herein, "terminal galactose" is intended to encompass unmodified galactose as well as derivatized or modified galactose, such as sulphonated galactose. Binding agent mimics or binding agent analogues, that have an affinity for underivatized, aqueous soluble $\beta(1-3)$ -glucan, are also included within the term, $\beta(1-3)$ -glucan binding agent. Compounds having these characteristics (the $\beta(1-3)$ -glucan binding agents) are suitable for use in the assays and methods described herein.

-13-

As a result of this discovery, methods are now available to capture, concentrate or purify $\beta(1-3)$ -glucans, including yeast or fungal soluble $\beta(1-3)$ -glucans, yeast or fungal insoluble $\beta(1-3)$ -glucans, as well as to capture, concentrate or purify $\beta(1-3)$ -glucan-containing organisms. In addition, assays to quantify the amount of $\beta(1-3)$ -glucan in a test sample are described herein; these assays can be used for diagnosis of fungal infections. Kits useful in the assays and methods are also described. The methods, assays and kits take advantage of the affinity of $\beta(1-3)$ -glucan binding agents, as described above, for high molecular weight, soluble $\beta(1-3)$ -glucan.

In accordance with the methods of the invention, a sample known to contain, or thought to contain, fungus or $\beta(1-3)$ -glucan-containing organisms is obtained. The test sample can be a liquid or a solid, and can originate from various sources, including complex animal sources (e.g., mammalian cells or tissues), plant cells or tissues, bacterial cells, viral cells, fungal cells, tissue cultures, environmental sources, food sources, or fermentation process sources. For example, if the test sample is from an animal source, such as from a human individual suspected of having a fungal infection, the test sample can be a biological fluid, such as blood (whole blood, whole blood serum or whole blood plasma), urine, feces, mucus, sputum, bile, ascites fluid, wound secretions, vaginal excretions, synovial fluid, cerebrospinal fluid, peritoneal lavage fluid, lung lavage fluid, ocular fluid, saliva or whole tissue extract; alternatively, the test sample can be solid specimen, such

-14-

as skin or other tissue. If the individual suspected of having a fungal infection is immunocompromized, the preferred test sample is a urine sample. If the sample is from a plant source, it can be a fluid or a solid specimen, such as plant tissue, plant tissue extract, fruit or fruit extracts, seeds or seed extracts, sap, or plant homogenates. The test sample can also be an environmental source such as water, soil, or soil extracts, or a food source such as prepared foodstuffs, that may be fungally contaminated. Alternatively, the test sample can be a sample from a fermentation process, such as fermentation broth.

If the test sample is high in protein, a de-proteinizing step, such as standard trichloroacetic acid or perchloric acid precipitation methods, or precipitation using a standard 70% ethanol precipitation method can be performed prior to performing the assay of the invention (*Methods in Enzymology Vol. 182: Guide to Protein Purification* (Deutscher, M.P., Ed., Academic Press, Inc, San Diego CA, 1990), Chapter 22, pp. 285-306). However, such a step is not necessary to perform the methods of the invention.

In a method of the invention, a $\beta(1-3)$ -glucan binding agent is used to capture or purify $\beta(1-3)$ -glucans and/or $\beta(1-3)$ -glucan-containing organisms from a test sample. The term, " $\beta(1-3)$ -glucan binding agent", as used herein, refers to compounds described above that have an affinity for underivatized, aqueous soluble $\beta(1-3)$ -glucan, including LacCer (HLM), LacCer (bovine), LacCer (porcine), GalCer (GalCer I, GalCer II, or a combination of GalCer I and

-15-

GalCer II), globotriaosylCer, and asialoganglioside-GM1. In a preferred embodiment, the $\beta(1-3)$ -glucan binding agent is LacCer or GalCer II, because of the high affinity of $\beta(1-3)$ -glucan for these compounds. In another preferred
5 embodiment, the $\beta(1-3)$ -glucan binding agent is GalCer; "GalCer", as used herein, can be either GalCer I, GalCer II, or a combination of GalCer I and GalCer II. More than one type of $\beta(1-3)$ -glucan binding agent can also be used concurrently.

10 In one embodiment of this method of the invention, the $\beta(1-3)$ -glucan binding agent(s) can be coupled to a solid phase (e.g., filter, membrane such as cellulose or nitrocellulose, plastic (e.g., microtiter plate, dipstick), glass (e.g., slide), bead (e.g., latex beads), particle,
15 organic resin, or other organic or non-organic solid phase) or a fluid (e.g., TRIS buffer or phosphate buffer) phase. Coupling the $\beta(1-3)$ -glucan binding agent(s) to the solid or fluid phase can be accomplished by standard methods, including, for example, air drying, heat drying, or
20 chemical reaction. In this embodiment of the method, the test sample is contacted with a $\beta(1-3)$ -glucan binding agent coupled to a solid or fluid phase, under conditions that are suitable for binding of any $\beta(1-3)$ -glucan (or $\beta(1-3)$ -glucan-containing organisms) that may be present in the
25 test sample to the $\beta(1-3)$ -glucan binding agent. $\beta(1-3)$ -glucan or a $\beta(1-3)$ -glucan-containing organism that is bound to a $\beta(1-3)$ -glucan binding agent is referred to herein as a "primary complex". The formation of primary complexes indicates that $\beta(1-3)$ -glucan, or a $\beta(1-3)$ -glucan-containing
30 organism, has been "captured" from the test sample. $\beta(1-$

-16-

3)-glucan or a $\beta(1-3)$ -glucan-containing organism that has been "captured" from the test sample is the $\beta(1-3)$ -glucan or the $\beta(1-3)$ -glucan-containing organism that is bound to a $\beta(1-3)$ -glucan binding agent.

5 In another embodiment of this method, the test sample can be attached (e.g., adsorbed, coated, coupled, covalently attached, attached by affinity binding) to a solid support, such as by dipping the solid support into the test sample, by dropwise application of a fluid test
10 sample with the solid support, or by smearing a solid test sample onto the solid support. If desired, the test sample can be mixed with a liquid, such as saline or any other appropriate biological buffer, prior to attachment to the solid support, such as, for example, in the case of solid
15 test samples. After the test sample is attached to a solid support (forming an "attached test sample"); a $\beta(1-3)$ -glucan binding agent (or more than one type of $\beta(1-3)$ -glucan binding agent) is contacted with the attached test sample, under conditions that are suitable for binding of
20 any $\beta(1-3)$ -glucan that may be present in the attached test sample to the $\beta(1-3)$ -glucan binding agent. $\beta(1-3)$ -glucan binding agent that is bound to any $\beta(1-3)$ -glucan or $\beta(1-3)$ -glucan-containing organism in the attached test sample is also referred to herein as a "primary complex".

25 In either embodiment of this method, any primary complexes that have formed can be isolated, in order to obtain, to isolate, to concentrate or to purify the $\beta(1-3)$ -glucan (or $\beta(1-3)$ -glucan containing organisms) from the test sample. The primary complexes can be obtained or
30 isolated using standard methods, such as by

-17-

immunoprecipitation or other means, resulting in concentrated or purified primary complexes, from which concentrated or purified $\beta(1-3)$ -glucan (or $\beta(1-3)$ -glucan-containing organisms) can be separated using standard methods (see *Current Protocols in Molecular Biology*, Vol. II, Ch. 10 (Ausubel, F. et al., eds., John Wiley & Sons, 1997)).

In another embodiment of the invention, the primary complexes can be detected, in an assay to determine whether $\beta(1-3)$ -glucan (or $\beta(1-3)$ -glucan-containing organisms) is present in the test sample. In addition, the amount of primary complexes can be determined: the concentration of the primary complexes correlates positively with the quantity of $\beta(1-3)$ -glucan (or $\beta(1-3)$ -containing organisms) present in the test sample. A variety of methods can be used to detect, and/or to determine the quantity of, the $\beta(1-3)$ -glucan, including detection of the $\beta(1-3)$ -glucan using an agent that selectively binds the primary complex, such as anti- β -glucan antibodies (monoclonal or polyclonal) or antibody fragments; detection of enzymatic reaction precipitated by $\beta(1-3)$ -glucan, such as by *Limulus* amebocyte lysate or *Limulus* lysate Factor G assay (Mori, T. et al., *Eur. J. Clin. Chem. Biochem* 35(7): 553-560 (1997); Hossai, M.A. et al., *J. Clin. Lab. Anal.* 11:73-77 (1997); Obayashi, T. et al., *J. Med. Vet. Mycology* 30:275-280 (1992), the entire teachings of each of which are incorporated herein by reference); use of enzymes that react with β -glucans; or other means. In a preferred embodiment, the *Limulus* lysate Factor G assay is used. In another embodiment of the method, the primary complexes can be detected through the

-18-

use of a detectable label on the $\beta(1-3)$ -glucan binding agent, such as a radionucleotide (e.g., radioummunoassay), dye, fluorescent compound, biotin or streptavidin. If desired, the quantity of primary complexes can be compared
5 to a standard curve generated with a known $\beta(1-3)$ -glucan standard.

In another embodiment of the invention, a competition assay can be used to determine the quantity of $\beta(1-3)$ -glucan (or $\beta(1-3)$ -glucan containing organisms) that is
10 present in the test sample. For example, labeled (for example, with radionucleotides, dyes, or fluorescent labels) underivatized, aqueous soluble $\beta(1-3)$ -glucan, or another soluble $\beta(1-3)$ -glucan, such as VHMW glucan, is incubated with the $\beta(1-3)$ -glucan binding agent and the test
15 sample, under conditions suitable for binding of underivatized, aqueous soluble $\beta(1-3)$ -glucan to its binding agent. Subsequently, the amount of primary complexes containing labelled, underivatized, aqueous soluble $\beta(1-3)$ -glucan is determined. This amount is compared with the
20 amount of primary complexes generated by incubation of labelled underivatized, aqueous soluble $\beta(1-3)$ -glucan with the $\beta(1-3)$ -glucan binding agent in a control sample (i.e., a sample having a known amount of unlabeled $\beta(1-3)$ -glucan) or a series of control samples (e.g., a standard curve).
25 The amount of $\beta(1-3)$ -glucan in the test sample is inversely proportional to the amount of primary complexes containing labelled, underivatized, aqueous soluble $\beta(1-3)$ -glucan.

Detection and quantitation of the presence of $\beta(1-3)$ -glucan, or of $\beta(1-3)$ -glucan containing organisms, is useful
30 in the diagnosis of fungemias or fungal contamination. To

-19-

diagnose fungal infection in an individual, for example, a sample, such as a biological fluid sample, is obtained from the individual. The sample is assayed for the presence of $\beta(1-3)$ -glucan, as described in detail above. The presence
5 of $\beta(1-3)$ -glucan in the test sample is indicative of the presence of a component of fungal cell walls, and is therefore indicative of fungal presence, contamination, or infections. Similarly, the presence of $\beta(1-3)$ -glucan in a sample from an environmental source, or a food source, is
10 indicative of fungal presence or contamination. In addition, quantitation of the amount of $\beta(1-3)$ -glucan, or of $\beta(1-3)$ -glucan containing organisms, can provide information regarding the severity of the infection or contamination. The methods and assays of the invention
15 provide accurate and specific identification of the presence of $\beta(1-3)$ -glucans in a test sample, thereby facilitating diagnosis and treatment of fungal infection and contamination.

Antibodies to $\beta(1-3)$ -glucan that are useful in the
20 methods and assays described above are also contemplated in the invention. Monoclonal or polyclonal antibodies can be produced using enriched or purified $\beta(1-3)$ -glucan preparations by standard techniques. For instance, polyclonal and/or monoclonal antibodies which bind to $\beta(1-3)$ -glucan are within the scope of the invention. A mammal,
25 such as a mouse, rat, hamster or rabbit, can be immunized with an immunogenic form of the $\beta(1-3)$ -glucan (i.e., an form that is capable of eliciting an antibody response). Techniques for conferring immunogenicity include
30 conjugation to carriers or other techniques well known in

-20-

the art. The $\beta(1-3)$ -glucan can be administered in the presence of an adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or serum. Standard ELISA or other immunoassays can be used
5 with the immunogen as antigen to assess the levels of antibody. Following immunization, antisera can be obtained, and if desired, polyclonal antibodies can be isolated from the serum. Monoclonal antibodies can also be produced by standard techniques which are wellknown in the
10 art (Kohler and Milstein, *Nature* 256:495-497 (1975); Kozbar et al., *Immunology Today* 4:72 (1983); and Cole et al., *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96 (1985)). Such antibodies can be used to identify the presence of $\beta(1-3)$ -glucans.

15 Kits useful in the methods and assays described above are also contemplated in the invention. Such a kit comprises primarily the components and reagents described for the methods and assays, such as a solid phase, detectable labels, $\beta(1-3)$ -glucan binding agent, and/or
20 labeled, underivatized, aqueous soluble, $\beta(1-3)$ -glucan. In one embodiment, the kit comprises lactosyl ceramide, galactosyl ceramide, globotriaosylceramide, and/or asialoganglioside-GM1 as a $\beta(1-3)$ -glucan binding agent. In a preferred embodiment, the $\beta(1-3)$ -glucan binding agent is
25 attached to a solid support, such as a filter, a membrane such as cellulose or nitrocellulose, a plastic support (e.g., microtiter plate, dipstick), a glass support (e.g., slide), beads (e.g., latex beads), particles, an organic resin, or other organic or non-organic solid phase.

-21-

The following Examples are offered for the purpose of illustrating the present invention and are not to be construed to limit the scope of this invention. The teachings of all references cited herein are incorporated
5 herein by reference.

EXAMPLES

EXAMPLE 1 Identification of Lactosyl ceramide as a binding agent for $\beta(1-3)$ -glucan

A. Materials

10 Lactosyl ceramide was purified from human leukocyte membranes (HLM) as described below. All other sphingolipids, ceramides, and phospholipids were from Sigma Chemical Co. (St. Louis, MO), except lactosyl ceramide (porcine) which was from Matreya, Inc. (Pleasant Gap, PA).
15 SOLVABLE™ was from DuPont (Boston, MA). 96-well polystyrene plates were from Corning (New York).

To prepare radioactively labeled underivatized, aqueous soluble $\beta(1-3)$ -glucan, underivatized, aqueous soluble $\beta(1-3)$ -glucan (PGG-Glucan, 17 mg; HPD0144, Alpha-
20 Beta Technology, Worcester, MA) was incubated with NaIO_4 (225 mg; Sigma, St. Louis, MO) in sterile pyrogen-free (SPF) water for 72 hours at room temperature. The periodate was quenched by the addition of 50 mg glycerol. The underivatized, aqueous soluble $\beta(1-3)$ -glucan was
25 dialyzed against SPF water, and then reductively labeled with 100 mCi of NaB^3H_4 (New England Nuclear, Boston, MA). Radioactively labeled underivatized, aqueous soluble $\beta(1-$

-22-

3)-glucan was separated from tritiated low molecular weight by-products by dialysis (10 K cut-off) and ultrafiltration. Purity of the labeled product was assessed by gel permeation chromatography.

5 B. Preparation of Human Neutrophils

Fresh whole blood was obtained from normal human volunteers using acid citrate dextrose as an anticoagulant. Following dextran sedimentation, cells were centrifuged (400 x g, 7 minutes) and resuspended in autologous plasma.
10 Cells were then layered over a Ficoll gradient (Lymphocyte Separation Medium; Organon Teknika, Durham, NC) and centrifuged (400 x g, 30 minutes). Cells recovered from the pellet were hypotonically lysed to remove residual RBC. The remaining cells were greater than 95% neutrophils as
15 judged by morphological criteria.

C. Preparation of Human Leukocyte Membranes

Buffy coat cells from human donors (Red Cross, Dedham, MA) were incubated in 3% dextran for 15-20 minutes at room temperature to separate leukocytes from red cells. The
20 leukocyte-rich supernatant was pelleted (500xg, 7 minutes) and washed once in ice cold phosphate buffered saline (PBS; Life Technologies, Grand Island, NY). All subsequent operations were performed at 4°C. The remaining red cells were removed by hypotonic lysis, and the leukocytes
25 recovered by centrifugation (850xg, 7 minutes). The cell pellet was resuspended in approximately 3-4x volume PBS, and protease inhibitors were added (5 mM EDTA, 40 µg/ml aprotinin, 1 µM pepstatin A, 1 µg/ml leupeptin, 50 µM

-23-

PMSF). The cells were disrupted by probe sonication (50 watts, 30 x 1 second pulses). Disruption of cells was monitored microscopically. Nuclei and remaining intact cells were removed by low speed centrifugation (700xg, 7 minutes). Occasionally, the low speed pellet was resonicated and subjected to another low speed centrifugation. The low speed supernatants were then collected by high speed ultracentrifugation (180,000xg, for 1 hour). Membrane pellets were resuspended in Hanks' balanced salt solution containing Ca^{++} and Mg^{++} (HBSS). Membrane protein was determined using the BCA or Comassie method (Pierce, Rockland, IL). Bovine serum albumin (Sigma, St. Louis, MO) was added to 1 mg/ml from a 10x stock, and the membranes stored in liquid nitrogen at 4-5 mg/ml. In some cases membranes were stored frozen without added protein; however, no change in binding was observed as a result of the different storage conditions.

In some cases, fresh human leukocytes were prepared from whole blood collected in acid citrate dextrose. Red blood cells were removed by dextran sedimentation and the leukocyte-rich layer was harvested and treated as described above. Finally, purified neutrophil and mononuclear leukocytes (including monocytes and lymphocytes) were prepared by resuspending the leukocyte-rich layer of cells in autologous plasma and layering the cells over Lymphocyte Separation Medium (LSM; Organon Technika) followed by centrifugation (700xg, 30 minutes). The neutrophil enriched pellet and the mononuclear cells present at the density interface were washed in ice cold PBS and membranes were prepared as described above. A stained Cytospin

-24-

(Shandon) preparation indicated that the neutrophil preparation was greater than 95% pure, and that the mononuclear preparation contained approximately 40%-50% monocytes.

5 D. Preparation of Membranes from Cell Lines

Non-adherent cell lines (U937 (Deposit CRL-1593) and HL-60 (Deposit CCL-240), American Type Culture Collection (ATCC), Rockville, MD) were collected by centrifugation (500xg, 7 minutes), washed in ice cold PBS, and the
10 membranes were prepared as described above. Lightly adherent cell lines were washed with ice cold PBS and removed by gentle scraping with a cell scraper (Costar). Greater than 90% of the cells maintained viability during this procedure as determined by dye exclusion. Cells were
15 resuspended in PBS and protease inhibitors. Tightly adherent cells were washed with ice cold PBS, then incubated with PBS plus the protease inhibitors described above. Cells were then removed by scraping and collected by centrifugation (500xg, 7 minutes). Membranes from
20 adherent cells were then prepared as described above.

E. Extraction of Membranes with
Chloroform/Methanol/Buffer

Human leukocyte membranes (5 mg protein/ml) prepared as described above were vortexed with 5 volumes of 3:2
25 chloroform/methanol (by volume) and centrifuged at 1,500 x g to separate phases. The upper aqueous and lower organic phases were removed from the proteinaceous interphase, combined, and concentrated under a stream of Argon to

-25-

approximately 50 μ l. The residue was resuspended in HBSS, sonicated briefly, and centrifuged (12,000 x g, 10 minutes) to pellet membranes. The pellet was resuspended in 500 μ l HBSS and 100 μ l was used per 350 μ l binding assay. Assays
5 for protein using the BCA reagent (Pierce) indicated that approximately 85% of the protein was removed from the resuspended fraction.

F. Purification of Lactosyl Ceramide (LacCer) from Human Leukocyte Membranes (HLM)

10 1. Extraction of Membranes with Chloroform/Methanol/Buffer

HLM (15 mg protein) in 1 mL of HBSS were extracted with chloroform (3 mL) and methanol (2 mL) by vortexing for one minute, followed by centrifugation at 1500 x g for 10
15 minutes to separate the layers. The upper layer and proteinaceous interphase were discarded. The lower layer was dried under a stream of argon, and resuspended in 200 μ L chloroform/methanol (10:1).

2. Thin Layer Chromatography Analysis of LacCer

20 Samples to be analyzed were spotted onto HPTLC silica gel plates and run in chloroform/methanol/water (80:20:2), along with commercially available LacCer standards. LacCer was visualized with the orcinol spray reagent (Schnaar, *Methods in Enzymology* 230:380 (Academic Press, 1994)).

25 3. Silica Gel Chromatography

100 μ L of the above extract was applied to a silica gel column (2 mL, 60 angstroms, 200-400 mesh) equilibrated

-26-

in chloroform. The column was washed with chloroform (8 mL), then acetone (16 mL), followed by elution of a glycosphingolipid fraction with acetone/methanol (9:1, 16 mL). The acetone/methanol fraction was concentrated to dryness, and resuspended in acetone/methanol (10:1).

4. DEAE-Sephadex Chromatography

The acetone/methanol fraction from silica chromatography was applied to a DEAE-Sephadex A-25 column (1 mL resin in the acetate form, prepared in chloroform/methanol (1:2)). The column was washed with 60 mL chloroform/methanol (1:2). Neutral glycosphingolipids were contained in this fraction, which was dried and resuspended in chloroform/methanol (5:1).

5. Final Silica Gel Chromatography

Fractions from DEAE-Sephadex were applied to a Silica gel column (25 x 0.8 cm) equilibrated in chloroform. The column was washed with chloroform (60 mL), then chloroform/methanol (7.5:1) (60 mL). LacCer was eluted with chloroform/methanol (5:1) (60 mL), then chloroform/methanol (2:1) (60 mL).

6. HPLC Fractionation

Fractionation of LacCer into individual components was carried out on a Hewlett Packard 1090 HPLC using a reverse-phase Symmetry C18 column (3.9 x 150 mm, Waters Associate, Milford, MA) and a mobile phase of 3.5% 0.2 M ammonium acetate in methanol at a flow rate of 1 mL/min. Peaks with u.v. absorbance at 206 nm were collected, dried

-27-

down, and analyzed by TLC to identify fractions containing LacCer. Isolated fractions were quantitated using a S.E.D.E.R.E. Sedex 55 evaporative mass detector (Alfortville France) at 45°C.

5 7. GC-MS Analysis

Three different analyses were performed on each isolated LacCer fraction. An aliquot was methanolized and the methanol solution extracted with hexane. The extracted fatty-acid methyl esters were analyzed by GC-MS (Irie et
10 al., *J. Biochem* 108: 531-536 (1990). The methanol layer was dried, trimethylsilylated, and dissolved in hexane. The resulting trimethylsilylated methyl glycosides were analyzed by GC-MS (Irie et al., 1990). A second aliquot was treated with ceramide glycanase (see below) and freeze
15 dried. The resulting acylated sphingosine and oligosaccharide were trimethylsilylated, dissolved in hexane, and analyzed by GC-MS on a HT-5 aluminum-clad capillary column.

G. Binding Assay in Reconstituted Membranes

20 Membranes were prepared from the receptor-negative cell line, U937 (Deposit CRL-1593, American Type Culture Collection (ATCC), Rockville, MD) and extracted with chloroform/methanol as described above. The upper and lower layers were combined after removal of the
25 proteinaceous interphase and dried under a stream of argon with the sample to be assayed for binding (lactosyl ceramide or fractions from the purification).

-28-

Alternatively, a mixture of purified phospholipids were dried with the sample for use in the binding assay. The phospholipid mixture contained phosphatidylcholine (132 μg), phosphatidylethanolamine (112 μg),
5 phosphatidylinositol (36 μg), and phosphatidylserine (56 μg).

The dried lipid/sample preparations were resuspended in HBSS (500 μL) by brief sonication, and centrifuged for 10 minutes at 12,000 x g. The supernatants from this spin
10 were discarded, and the pellets were resuspended in HBSS (560 μL). Aliquots of 280 μL were added to tubes containing saline (35 μL) or unlabelled, underivatized, aqueous soluble $\beta(1-3)$ -glucan (35 μL of 10 mg/mL stock), and ^3H -underivatized, aqueous soluble $\beta(1-3)$ -glucan (35 μL
15 of a 10 $\mu\text{g}/\text{mL}$ stock). Assays were incubated at 37°C for one hour, after which time three 100 μL aliquots were removed and centrifuged in microfuge tubes at 12,000 x g for 5 minutes at room temperature. The supernatants were discarded and the pellets were rinsed with 150 μL of HBSS.
20 Pellets were then dissolved in SOLVABLE™, scintillation fluid was added, and radioactivity was measured.

H. Binding Assay in 96-Well Plates

Lactosyl ceramide or the sample to be measured was suspended in ethanol. Aliquots as specified were added in
25 triplicate to the wells of a 96-well plate and air dried. The following components were premixed, then 100 μL was added to each well: saline (10 μL) or unlabelled, underivatized, aqueous soluble $\beta(1-3)$ -glucan (10 μL of a 10 mg/mL stock), ^3H -underivatized, aqueous soluble $\beta(1-3)$ -

-29-

glucan (10 μ L of a 10 μ g/ml stock), and HBSS (80 μ L). Plates were incubated at 37°C for 1.5 to 2 hours, then supernatants were removed from each well and discarded. Wells were rinsed with HBSS (200 μ L) and SOLVABLE™ (100 μ L) was added. The plate was incubated at 60°C for 5 minutes, then supernatants were removed and counted.

I. Binding Assay - Leukocyte Membranes
Oil/Sucrose Method

Membranes were diluted to 2 to 5 mg/ml in HBSS with and without 1 mg/ml BSA. The reaction mixture consisted of 280 μ l membranes (2-4 mg/ml final concentration), 35 μ l saline or test sample (in various concentrations), and 35 μ l radioactively labeled underivatized, aqueous soluble β (1-3)-glucan (1 μ g/ml final concentration). Binding was allowed to proceed for 60 to 120 minutes at 37°C. At the end of the incubation, 100 μ l aliquots of reaction mixture were layered on top of a double layer density gradient consisting of 100 μ l dibutyl phthalate (lower layer) and 100 μ l 8% sucrose in PBS (upper layer) in 400 μ l centrifuge tubes (Brinkman). The tubes were spun at 15,000xg for 4-5 minutes and the tips containing the membrane pellets were removed, incubated in 300 μ l SOLVABLE™ (New England Nuclear, Boston, MA) overnight at 50°C to dissolve the pellet, and then radioactivity determined by liquid scintillation counting. No radioactivity was found in the oil layer in the absence of added membranes. Alternatively, membranes were centrifuged directly in their incubation tubes at 15,000xg for 4-5 minutes at 37°C, the

-30-

pellet washed with HBSS, then pellets solubilized and radioactivity determined by liquid scintillation counting.

Non-Oil/Sucrose Method

An alternative procedure to that using the oil/sucrose gradient involved centrifuging 100 μ l aliquots of the binding assay in microfuge tubes at 12,000 x g, for five minutes, followed by rinsing the resultant pellet with HBSS. Pellets were then dissolved in SOLVABLE™ and radioactively determined as above.

10 J. Generation of Monoclonal Antibodies to PGG Glucan
Balb/c female mice, aged 6 weeks (Charles River, Wilmington, MA) were used to generate monoclonal antibodies. Four mice were injected subcutaneously with 25 μ g of very high molecular weight β (1-3)-glucan (Alpha-Beta Technology, Inc., Worcester, MA) which had been mixed 1:2
15 with TITERMAX™ adjuvant (Sigma, St. Louis, MO). After three weeks, plasma samples were collected and assayed for the presence of antibodies to β (1-3)-glucan by a direct ELISA screening protocol, as follows: 100 μ l of a 10 μ g/ml
20 solution of PGG-glucan (Alpha-Beta Technology, Worcester, MA), or mannan (Sigma, St. Louis, MO) in phosphate buffered saline (PBS, Sigma, St. Louis, MO) was added to polystyrene Universal Binding microtiter plates (Corning Costar, Cambridge, MA) and incubated at room temperature for 1
25 hour. The plates were decanted and exposed to ultraviolet irradiation (1200 microjoules) for five minutes to facilitate cross-linking to the polystyrene. The plates were blocked with 1% gelatin (Difco, Detroit, MI) in PBS

-31-

for 1 hour at 37°C, and decanted. A sample of cell culture supernatant was added to a PGG-glucan-coated plate and to a mannan-coated plate. Cell culture media (RPMI 1640, Sigma, St. Louis, MO) was used as the negative control. The
5 sample were incubated for 1 hour at 37°C then washed 5 times with PBS. Goat anti-mouse IgA, IgG, and IgM conjugated to horseradish peroxidase (Kirkegaard and Perry Labs, Gaithersburg, MD) was diluted 1:1000 in 50% fetal bovine serum (FBS, Sigma, St. Louis, MO) in Tris/HCl buffer
10 (Sigma, St. Louis, MO). The samples were incubated for 1 hour at 37°C, then washed 5 times with PBS. o-phenylenediamine dihydrochloride (Sigma, St. Louis, MO) was added and the plates were incubated 5-10 minutes at room temperature until strong color developed. H₂SO₄ (1 N) was
15 added to each well to stop the reaction, and the color development was read in a spectrophotometer set to an optical density (OD) of 492 nm. A positive result was determined to be an OD reading on the PGG-glucan-coated plate which was at least twice the OD of the mannan-coated
20 plate and the negative control.

One mouse had a moderate titer. This mouse was injected intravenously with 25 µL of VHMW β(1-3)-glucan in saline. Three days later, the spleen was removed, and a fusion with Sp2/0 mouse myeloma cells (Deposit CRL-1581,
25 American Type Culture Collection (ATCC), Rockville, MD) was performed (Lane, R. J. *Imm. Meth.* 81:223-228 (1985). Hybridomas were screened two weeks after fusion, by the direct ELISA screening protocol described above. Thirteen of 251 hybridomas were positive in the ELISA screening
30 protocol and were isolated for expansion and cloning.

-32-

After expansion, the remaining viable hybridomas were retested; positive clones were isotyped with a kit (Sigma, St. Louis, MO) and all proved to be IgM. The hybridomas were cloned, subcloned, and ascites fluid was produced

- 5 (Mishell and Shiigi, *Selected Methods in Cellular Immunology*, W.H. Freeman and Co., San Francisco, CA, 1980). The antibodies produced included four antibodies that were identified as PGG-Glucan-detection antibody (BfD) I, BfD II, BfD III, and BfD IV (used in Example 2, below).

10 EXAMPLE 2 GalCer Capture and Antibody Detection of β -
Glucans in Biological Fluids

- Galactocerebroside Type II (Gal-Cer II) from bovine brain (Sigma, St. Louis, MO) was dissolved in 200 proof ethanol to a stock solution at a concentration of 1 mg/mL, rediluted 1:10 in ethanol, and sonicated before use. Sterile polystyrene 96-well ELISA microtiter plates (Corning Costar, Cambridge, MA) were coated with 20 μ L per well of 0.1 mg/ml Gal-Cer II per well, and the ethanol was allowed to evaporate until dry. 150 μ L of a blocking solution of Tris-buffered saline (TBS 0.05 M Tris-HCl, 0.15 M NaCl, both obtained from J.T. Baker (Phillipsburg, NJ)) and 1% bovine serum albumin (Sigma, St. Louis, MO) was added to each well. The blocking solution was incubated at 37°C for 30 minutes, or overnight at 4°C. Plates were decanted and blotted immediately prior to use.

Biological samples high in protein, such as serum, plasma, or cerebral spinal fluid (CSF) were treated with a de-proteinating step, such as standard trichloroacetic acid or perchloric acid precipitation methods (Obayashi, T., J.

-33-

Lab. Clin. Med. 104(3):321-330 (1984). These samples were subsequently neutralized and concentrated to their original volumes. Alternatively, precipitation using a standard 70% ethanol precipitation method (*Methods in Enzymology* Vol.

5 182: *Guide to Protein Purification* (Deutscher, M.P., Ed., Academic Press, Inc, San Diego CA, 1990), Chapter 22, pp. 285-306) was used to isolate analyte from proteinaceous biological fluids. Biological samples that did not have a high protein content, such as urine, needed no treatment.

10 To prepare a standard curve, underivatized, aqueous soluble β (1-3)-glucan (Alpha-Beta Technology, Worcester MA), or other relevant underivatized, aqueous soluble β (1-3)-glucan was subjected to the same treatment that was required for the biological sample. The standard curve was
15 a range of doubling dilutions from 10 ng/mL to 0.15 ng/mL as measured by hexose concentration of the purified glucan. The concentration of the glucan in the unknown was calculated using this standard curve.

Biological samples (treated, if necessary, with a
20 deproteinating step as described above) were added to the coated and blocked microtiter plate in volumes of 100 μ l/well. The analytes were incubated 4-24 hours at 37°C. At the end of the incubation time, the plate was decanted and washed three times with TBS buffer (at least 350
25 μ l/well). The monoclonal antibody, BfD IV (Alpha-Beta Technology, Worcester, MA) was diluted in blocking diluent to a concentration of 0.1 μ g/mL and 100 μ l was added to each well of the microtiter plate. The plate was incubated for 2 hours at 37°C. At the end of the incubation time,
30 the plate was decanted and washed three times with TBS

-34-

buffer (at least 350 μ l/well). Previously titrated, commercially available goat anti-mouse IgM antibody conjugated to horseradish peroxidase (Southern Biotechnology Associated, Birmingham, AL) was added, 100 μ l/well (1:16,000), and incubated for 1 hour at 37°C. At the end of the incubation time, the plate was decanted and washed three times with TBS buffer (at least 350 μ l/well). Tetramethylbenzidine (TMB), 0.4 g/L in an organic base (Kirkegaard & Perry Laboratories, inc., Gaithersburg, MD) was added and incubated at room temperature for a previously established time (approximately 10 to 60 minutes) that was determined by cross-titering with various concentrations of the goat anti-mouse IgM antibody conjugation to horseradish peroxidase. Each well of the microtiter plate was read in a spectrophotometer at 450 nanometers to determine the optical density. The results, shown in Figure 3, demonstrate the ability of GalCer to capture glucan.

EXAMPLE 3 Comparison of β (1-3)-Glucan Binding Agents

A comparative analysis of the ability of galactocerebroside (GalCer), glucocerebroside (GlcCer) and lactocerebroside (LacCer) to bind underivatized, aqueous soluble β (1-3)-glucan was conducted. 96-well plates were coated with 1 μ g/well of a sphingolipid (GalCer, GluCer or LacCer) or with ethanol (negative control), blocked with 150 μ l/well 1% gelatin (Difco, MI), and incubated with various concentrations of underivatized, aqueous soluble β (1-3)-glucan from *Saccharomyces cerevisiae*; subsequently, *Limulus* amebocyte lysate was added, and enzyme activation

-35-

of Factor G was monitored (Morita, T. et al., *FEBS Letters* 129:318-321 (1981); see also Tanaka, S. et al., *Carbohydrate Res.* 218:167-174 (1991); and Makami, T. et al., *Microbiol. Immunol.* 26(5):403-409 (1982), the entire
5 teachings of which are incorporated herein by reference). Results, shown in Figure 4, indicate that GalCer and LacCer bind significantly more underivatized, aqueous soluble $\beta(1-3)$ -glucan at 10,000 pg/mL than GluCer or the negative control.

10 EXAMPLE 4 Comparison of GalCer and LacCer $\beta(1-3)$ Glucan Binding Agents

The ability of GalCer and LacCer to capture soluble $\beta(1-3)$ -glucan was compared by coating a predetermined optimal concentration of either sphingolipid (20 μ l or a
15 0.1 mg/ml solution) on a 96-well microtiter plate, and using a titrated preparation of glucan to detect the sphingolipid. Results, shown in Figure 5, demonstrate that GalCer bound approximately three times as much titrated material as LacCer.

20 EXAMPLE 5 Ability of GalCer to Capture Different Soluble $\beta(1-3)$ -glucan Aggregates

An experiment was conducted to explore the ability of GalCer to capture various soluble $\beta(1-3)$ -glucans, including PGG-Glucan (MOL WT = approximately 100,000), random coil
25 glucan (molecular weight of approximately 6,000), single chain glucan (molecular weight of approximately 14,000), triple helix glucan (molecular weight of approximately 160,000) and very high molecular weight glucan (molecular

-36-

weight of approximately 6,000,000). 96-well plates were coated with 2 μ g/well 1% gelatin, and incubated with various concentrations of soluble β (1-3)-glucan aggregates from *Saccharomyces cerevisiae*; subsequently, *Limulus* 5 amebocyte lysate was added, and enzyme activation of Factor G was monitored (Morita, T. et al., *FEBS Letters* 129:318-321 (1981)). The results, shown in Figure 6, demonstrate that GalCer captures only glucans having high molecular weight (PGG-glucan, very high molecular weight glucan, and 10 triple helix glucan).

EXAMPLE 6 Identification of Aqueous Soluble Glucan in a Biological Matrix

A dilution series of crude preparation of an aqueous soluble glucan from *S. cerevisiae* was added to normal human 15 urine, to human plasma (+1-PCA treatment) and to Tris-buffered saline. The samples were assayed as described in Example 2, using GalCer, and a dilution curve generated. The dilution curve, shown in Figure 7, demonstrate that GalCer could capture the aqueous soluble glucan in urine, 20 plasma and PCA-treated plasma, and allow its detection.

EXAMPLE 7 Comparison of Sensitivity of β (1-3)-Glucan Antibodies

A panel of monoclonal antibodies, generated as described in Example 1 (J), was used to detect soluble β (1- 25 3)-glucan which had been bound to GalCer, as described in Example 2. BfD I, BfD II, BfD III, and BfD IV, as well as a commercially available antibody from B. Stone (Biosupplies, Parkville, Victoria, Australia), were used.

-37-

The results, shown in Figure 8, demonstrate the BfD IV was the most sensitive.

EXAMPLE 8 Assessment of the Binding Capability of Antibody
BfD IV

5 Various carbohydrate polymers were added to a competition ELISA to assess the specificity of the monoclonal antibody BfD IV. Polystyrene Universal Binding 96-well microtiter plates (Corning Coster) were coated with 100 μ l of a 0.5 μ l/mL solution of PGG-Glucan in phosphate-
10 buffered saline (PBS from Sigma). The plate was incubated for 1 hour at 37°C, decanted and exposed to ultraviolet irradiation (1200 microjoules) for 5 minutes to facilitate cross-linking to the polystyrene. The plates were blocked with PBS plus 1% gelatin (Difco) for 30 minutes at 37°C.
15 Two hundred μ l of a 1/1000 dilution of monoclonal antibody BfD IV was mixed with the test compounds which were diluted in a range from 100-0.001 μ g/mL. PGG-Glucan was included as a positive control test compound. The mixture was incubated for 1 hour at 37°C. The plates were washed 3
20 times with wash buffer consisting of PBS plus 0.1% Tween 20 (polyoxyethylenesorbitan monolaurate from Sigma) and 100 μ l of the antibody-test compound mixture was added. The mixture was incubated on the plate for 2 hours at 37°C. The plates were washed three times and goat anti-mouse IgM
25 conjugated to horseradish peroxidase (Kirkegaard and Perry Labs) was added and incubated for 1 hour at 37°C. The plates were washed three times and TMB (Kirkegaard and Perry Labs) was added and incubated for 5 minutes at room temperature. Stop solution (Kirkegaard and Perry Labs) was

-38-

added and the color development was read on a spectrophotometer set to an optical density (OD) of 450 nm. Percent competition was determined by dividing the O.D. of the test compound (100 μ g/mL concentration) by the O.D. of the PGG-Glucan positive control (100 μ g/mL concentration) and multiplying the result by 100.

The results, shown in Table 4, demonstrate that BfD IV bound specifically to PGG-Glucan (BETAFECTIN™), triple helix conformer, VHMW conformer, laminaritetraose, laminaritriose, and partially bound to scleroglucan and pustulan.

-39-

Table 4 Binding Ability of BfD IV

<u>Compound</u>		<u>% Cross-reactive</u>
	PGG-Glucan ¹	100
	Single Chain Conformer ¹	0
5	Random Coil conformer ¹	0
	VHMW Conformer ¹	100
	Chitobiose ²	0
	Curdlan ³	10
	Gentiobiose ⁴	0
10	Endotoxin ⁴	0
	Glucosamine ⁴	0
	Scleroglucan ⁵	60
	Chitosan ⁶	0
	Pustulan ⁷	65
15	Dextran ⁴	0
	Laminariheptaose ²	0
	Laminarihexaose ²	0
	Laminaripentaose ²	0
	Laminaritetraose ²	100
20	Laminaritriose ²	100
	Laminaribiose ²	25
	Laminarin ⁴	0
	Glycogen ⁸	0
	Mannan ⁴	0

- 25 1- Alpha-Beta Technology, Inc., Worcester, MA
 2- Seikagaku, Tokyo, Japan
 3- Wako, Osaka, Japan
 4- Sigma Chemicals, St. Louis, MO
 5- Sanofi Bio-industries, Paris, France
 30 6- JT Baker, Phillipsburg, NJ
 7- Calbiochem, La Jolla, CA
 8- ICN, Costa Mesa, CA

-40-

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention
5 described herein. Such equivalents are intended to be encompassed by the following claims:

-41-

CLAIMS

What is claimed is:

1. A method of isolating $\beta(1-3)$ -glucan from a sample, comprising the steps of:
 - 5 a. contacting a sample containing $\beta(1-3)$ -glucan with a $\beta(1-3)$ -glucan binding agent, under conditions that are suitable for binding of $\beta(1-3)$ -glucan to the $\beta(1-3)$ -glucan binding agent to form primary complexes of $\beta(1-3)$ -glucan bound to $\beta(1-3)$ -glucan binding agent;
10 b. isolating the primary complexes; and
c. obtaining $\beta(1-3)$ -glucan from the primary complexes.
2. The method of Claim 1, wherein the $\beta(1-3)$ -glucan
15 binding agent is coupled to a solid phase.
3. The method of Claim 2, wherein the solid phase is selected from the group consisting of: filters, membranes, beads, particles, organic resin, microtiter plates and slides.
- 20 4. The method of Claim 1, wherein the $\beta(1-3)$ -glucan binding agent is selected from the group consisting of: lactosyl ceramide, galactosyl ceramide, globotriaosylceramide and asialoganglioside-GM1.
- 25 5. The method of Claim 1, wherein the $\beta(1-3)$ -glucan binding agent is lactosyl ceramide or galactosyl ceramide.

-42-

6. A method of isolating $\beta(1-3)$ -glucan-containing organisms from a sample, comprising the steps of:
- a. contacting a sample containing $\beta(1-3)$ -glucan-containing organisms with a $\beta(1-3)$ -glucan binding agent, under conditions that are suitable for binding of $\beta(1-3)$ -glucan to the $\beta(1-3)$ -glucan binding agent to form primary complexes of $\beta(1-3)$ -glucan bound to $\beta(1-3)$ -glucan binding agent;
 - b. isolating the primary complexes; and
 - c. obtaining $\beta(1-3)$ -glucan-containing organisms from the primary complexes.
7. A method of detecting the presence of $\beta(1-3)$ -glucan in a sample, comprising the steps of:
- a. contacting a sample to be tested for the presence of $\beta(1-3)$ -glucan with a $\beta(1-3)$ -glucan binding agent, under conditions that are suitable for binding of $\beta(1-3)$ -glucan, to the $\beta(1-3)$ -glucan binding agent, to form primary complexes of $\beta(1-3)$ -glucan bound to $\beta(1-3)$ -glucan binding agent; and
 - b. detecting the primary complexes formed in step (a),
- wherein the presence of primary complexes is indicative of the presence of $\beta(1-3)$ -glucan in the sample.
8. The method of Claim 7, wherein the $\beta(1-3)$ -glucan binding agent is attached to a solid phase.

-43-

9. The method of Claim 8, wherein the solid phase is selected from the group consisting of: filters, membranes, beads, particles, organic resin, microtiter plates and slides.
- 5 10. The method of Claim 7, wherein the sample is attached to a solid phase.
11. The method of Claim 10, wherein the solid phase is selected from the group consisting of: filters, membranes, beads, particles, organic resin, microtiter
10 plates and slides.
12. The method of Claim 7, wherein the $\beta(1-3)$ -glucan binding agent is selected from the group consisting of: lactosyl ceramide, galactosyl ceramide, globotriaosylceramide and asialoganglioside-GM1.
- 15 13. The method of Claim 12, wherein the $\beta(1-3)$ -glucan binding agent is lactosyl ceramide or galactosyl ceramide.
14. The method of Claim 7, wherein the sample is from an animal source.
- 20 15. The method of Claim 14, wherein the sample is a biological fluid.
16. The method of Claim 7, wherein the sample is from a plant source.

-44-

17. The method of Claim 7, wherein the sample is from an environmental source.
18. The method of Claim 7, wherein the sample is from a food source.
- 5 19. The method of Claim 7, wherein the sample is from a fermentation source.
20. The method of Claim 7, wherein the primary complexes are detected with a detectable label.
21. The method of Claim 20, wherein the detectable label
10 is selected from the group consisting of:
radionucleotides, dyes, fluorescent compounds, biotin
and streptavidin.
22. The method of Claim 7, wherein the primary complexes are detected with an antibody.
- 15 23. The method of Claim 22, wherein the antibody is an antibody to $\beta(1-3)$ -glucan.
24. The method of Claim 22, wherein the antibody is an antibody to $\beta(1-3)$ -glucan binding agent.
25. A method of detecting the presence of $\beta(1-3)$ -glucan-
20 containing organisms in a sample, comprising the steps of:

-45-

- 5 a. contacting a sample to be tested for the presence
 of $\beta(1-3)$ -glucan-containing organisms with a $\beta(1-3)$ -
 glucan binding agent, under conditions that
 are suitable for binding of $\beta(1-3)$ -glucan, to the
 $\beta(1-3)$ -glucan binding agent to form primary
 complexes of $\beta(1-3)$ -glucan-containing organisms
 bound to $\beta(1-3)$ -glucan binding agent; and
 b. detecting the primary complexes formed in step
 (a),
10 wherein the presence of primary complexes is
 indicative of the presence of $\beta(1-3)$ -glucan-containing
 organisms in the sample.
26. A method of quantifying the amount of $\beta(1-3)$ -glucan in
 a sample, comprising the steps of:
- 15 a. contacting a sample to be tested with a $\beta(1-3)$ -
 glucan binding agent, under conditions that are
 suitable for binding of $\beta(1-3)$ -glucan, to the
 $\beta(1-3)$ -glucan binding agent, to form primary
 complexes of $\beta(1-3)$ -glucan bound to $\beta(1-3)$ -glucan
20 binding agent;
 b. isolating the primary complexes formed in step
 (a); and
 c. quantifying the primary complexes,
 wherein the amount of $\beta(1-3)$ -glucan in the sample
25 correlates with the amount of primary complexes.
27. A method of quantifying the amount of $\beta(1-3)$ -glucan in
 a sample, comprising the steps of:
- a. contacting a sample to be tested with a $\beta(1-3)$ -
 glucan binding agent and a labeled,

-46-

- underivatized, aqueous soluble $\beta(1-3)$ -glucan,
under conditions that are suitable for binding of
 $\beta(1-3)$ -glucan, to the $\beta(1-3)$ -glucan binding agent
to form primary complexes of underivatized,
5 aqueous soluble $\beta(1-3)$ -glucan bound to $\beta(1-3)$ -
glucan binding agent; and
b. determining the amount of primary complexes
formed in step (a),
wherein the amount of $\beta(1-3)$ -glucan in the sample is
10 inversely related to the amount of primary complexes.
28. A method of diagnosing infection by a $\beta(1-3)$ -glucan-
containing organism in an individual, comprising the
steps of:
- a. 15 contacting a sample from the individual with a
 $\beta(1-3)$ -glucan binding agent, under conditions
that are suitable for binding of $\beta(1-3)$ -glucan,
to the $\beta(1-3)$ -glucan binding agent, to form
primary complexes of $\beta(1-3)$ -glucan bound to $\beta(1-3)$ -
glucan binding agent; and
20 b. detecting the primary complexes formed in step
(a),
wherein the presence of primary complexes is
indicative of infection by a $\beta(1-3)$ -glucan-containing
organism.
- 25 29. A kit useful in detecting the presence of $\beta(1-3)$ -
glucan, comprising a $\beta(1-3)$ -glucan binding agent and
an antibody to underivatized, aqueous soluble, $\beta(1-3)$ -
glucan.

-47-

30. The kit of Claim 29, wherein the $\beta(1-3)$ -glucan binding agent is selected from the group consisting of:
lactosyl ceramide, galactosyl ceramide,
globotriaosylceramide, and asialoganglioside-GM1.
- 5 31. An antibody to underivatized, aqueous soluble,
 $\beta(1-3)$ -glucan.
32. The antibody of Claim 31, wherein the antibody is
selected from the group consisting of: BfD I, BfD II,
BfD III and BfD IV.
- 10 33. An antibody that binds specifically to a $\beta(1-3)$ glucan
selected from the group consisting of: PGG-Glucan,
triple helix conformer, very high molecular weight
conformer, laminaritetraose and laminaritriose.

1/4




FIG. 1




FIG. 2

2/4




FIG. 3




FIG. 4

3/4




FIG. 5




FIG. 6

4/4




FIG. 7




FIG. 8

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/24014

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 G01N33/566 G01N33/569

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PATENT ABSTRACTS OF JAPAN vol. 017, no. 200 (C-1050), 20 April 1993 & JP 04 346791 A (TAITOU KK), 2 December 1992 see abstract	7, 14, 15, 17, 31
A	---	1-3, 6, 8-11, 20, 22, 23, 25-29, 32, 33
X	EP 0 805 161 A (SEIKAGAKU KOGYO CO LTD) 5 November 1997	1-3, 6-11, 20-22, 24-28
A	see the whole document ---	14-19, 29
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

24 March 1999

Date of mailing of the international search report

16/04/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gundlach, B

INTERNATIONAL SEARCH REPORT

Inter. Classification No.

PCT/US 98/24014

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 41439 A (ALPHA BETA TECHNOLOGY ;WAKSHULL ERIC (US); MACKIN WILLIAM M (US);) 6 November 1997 see abstract see page 7, line 27 - line 33 see page 23, line 7 - page 24, line 14; figure 15; table 3 see page 27, line 33 - page 28, line 23 -----	1-30
A	EP 0 598 903 A (SEIKAGAKU KOGYO CO LTD) 1 June 1994 see abstract -----	1-30
P,A	ZIMMERMAN, JANET W. ET AL: "A novel carbohydrate-glycosphingolipid interaction between α .beta.-(1-3) glucan immunomodulator, PGG- glucan, and lactosylceramid of human leukocytes" J. BIOL. CHEM. (1998), 273(34), 22014-22020 CODEN: JBCHA3;ISSN: 0021-9258, 1998, XP002096763 see the whole document -----	1-30

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/24014

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0805161 A	05-11-1997	CN 1185161 A WO 9606858 A	17-06-1998 07-03-1996
WO 9741439 A	06-11-1997	AU 3117197 A EP 0900379 A	19-11-1997 10-03-1999
EP 0598903 A	01-06-1994	JP 4287696 A JP 4285859 A AT 157403 T AU 658408 B AU 1544292 A CA 2082962 A DE 69221879 D DE 69221879 T DK 598903 T FI 925149 A WO 9216651 A NO 303179 B US 5681710 A	13-10-1992 09-10-1992 15-09-1997 13-04-1995 21-10-1992 15-09-1992 02-10-1997 29-01-1998 02-03-1998 12-11-1992 01-10-1992 08-06-1998 28-10-1997